Mitogen-activated protein kinase 14 (p38α):MAP kinase-activated protein kinase 2 (MK2) protein-protein interface (p38α:MK2 PPI)

Mitogen-activated protein kinase 14 (MAPK14), or p38α, is a pivotal enzyme in the MAP kinase signaling pathway, primarily responsible for responding to environmental stress and regulating the production of pro-inflammatory cytokines (Source: UniProt P47811). A key mechanism of its action is the phosphorylation of its downstream substrate, MAP kinase-activated protein kinase 2 (MK2), which occurs through a specific protein-protein interface (PPI) known as the docking site (Source: PubMed 24635520). This p38α:MK2 interaction is crucial for the post-transcriptional regulation of inflammatory genes, including TNF-α and IL-6, by stabilizing their mRNA (Source: PubMed 29733160). Historically, ATP-competitive inhibitors of p38α failed in clinical trials due to significant side effects and a lack of long-term efficacy. Consequently, the p38α:MK2 PPI has emerged as a promising alternative therapeutic target, offering a way to selectively disrupt the pro-inflammatory signaling branch while minimizing off-target effects associated with broad kinase inhibition (Source: PubMed 15631441). Research into small molecules that block this interface aims to provide safer and more effective treatments for chronic inflammatory conditions like rheumatoid arthritis and various malignancies.

Other names

p38-MK2 complexMAPK14-MAPKAPK2 interfacep38alpha-MK2 docking sitep38-MK2 interactionMAPK14:MAPKAPK2 PPI

Inhibition of protein-protein interaction (PPI) by blocking the docking of MK2 to the p38α kinase, thereby preventing MK2 activation and downstream cytokine signaling (Source: PubMed 24635520).